Vanderwall Elizabeth R, Barrow Kaitlyn A, Rich Lucille M, Read David F, Trapnell Cole, Okoloko Oghenemega, Ziegler Steven F, Hallstrand Teal S, White Maria P, Debley Jason S
bioRxiv. 2021 Nov 23:2021.11.20.469409. doi: 10.1101/2021.11.20.469409.
Common alphacoronaviruses and human rhinoviruses (HRV) induce type I and III interferon (IFN) responses important to limiting viral replication in the airway epithelium. In contrast, highly pathogenic betacoronaviruses including SARS-CoV-2 may evade or antagonize RNA-induced IFN I/III responses.
In airway epithelial cells (AECs) from children and older adults we compared IFN I/III responses to SARS-CoV-2 and HRV-16, and assessed whether pre-infection with HRV-16, or pretreatment with recombinant IFN-β or IFN-λ, modified SARS-CoV-2 replication. Bronchial AECs from children (ages 6-18 yrs.) and older adults (ages 60-75 yrs.) were differentiated to generate organotypic cultures. In a biosafety level 3 (BSL-3) facility, cultures were infected with SARS-CoV-2 or HRV-16, and RNA and protein was harvested from cell lysates 96 hrs. following infection and supernatant was collected 48 and 96 hrs. following infection. In additional experiments cultures were pre-infected with HRV-16, or pre-treated with recombinant IFN-β1 or IFN-λ2 before SARS-CoV-2 infection.
Despite significant between-donor heterogeneity SARS-CoV-2 replicated 100 times more efficiently than HRV-16. IFNB1, INFL2, and CXCL10 gene expression and protein production following HRV-16 infection was significantly greater than following SARS-CoV-2. IFN gene expression and protein production were inversely correlated with SARS-CoV-2 replication. Treatment of cultures with recombinant IFNβ1 or IFNλ2, or pre-infection of cultures with HRV-16, markedly reduced SARS-CoV-2 replication.
In addition to marked between-donor heterogeneity in IFN responses and viral replication, SARS-CoV-2 elicits a less robust IFN response in primary AEC cultures than does rhinovirus, and heterologous rhinovirus infection, or treatment with recombinant IFN-β1 or IFN-λ2, markedly reduces SARS-CoV-2 replication.
常见的甲型冠状病毒和人鼻病毒(HRV)可诱导I型和III型干扰素(IFN)反应,这对于限制气道上皮细胞中的病毒复制很重要。相比之下,包括SARS-CoV-2在内的高致病性β冠状病毒可能逃避或拮抗RNA诱导的I/III型IFN反应。
在儿童和老年人的气道上皮细胞(AEC)中,我们比较了I/III型IFN对SARS-CoV-2和HRV-16的反应,并评估了HRV-16预感染,或重组IFN-β或IFN-λ预处理是否会改变SARS-CoV-2的复制。将儿童(6至18岁)和老年人(60至75岁)的支气管AEC进行分化以生成器官型培养物。在生物安全3级(BSL-3)设施中,用SARS-CoV-2或HRV-16感染培养物,并在感染后96小时从细胞裂解物中收获RNA和蛋白质,在感染后48小时和96小时收集上清液。在其他实验中,在SARS-CoV-2感染之前,用HRV-16对培养物进行预感染,或用重组IFN-β1或IFN-λ2进行预处理。
尽管供体之间存在显著的异质性,但SARS-CoV-2的复制效率比HRV-16高100倍。HRV-16感染后IFNB1、INFL2和CXCL10基因表达及蛋白质产生显著高于SARS-CoV-2感染后。IFN基因表达和蛋白质产生与SARS-CoV-2复制呈负相关。用重组IFNβ1或IFNλ2处理培养物,或用HRV-16预感染培养物,可显著降低SARS-CoV-2的复制。
除了IFN反应和病毒复制在供体之间存在明显的异质性外,SARS-CoV-2在原代AEC培养物中引发的IFN反应比鼻病毒弱,而异源鼻病毒感染或用重组IFN-β1或IFN-λ2处理可显著降低SARS-CoV-2的复制。